Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method
Author
Nasa, PrashantAzoulay, Elie
Khanna, Ashish K
Jain, Ravi
Gupta, Sachin
Javeri, Yash
Juneja, Deven
Rangappa, Pradeep
Sundararajan, Krishnaswamy
Alhazzani, Waleed
Antonelli, Massimo
Arabi, Yaseen M
Bakker, Jan
Brochard, Laurent J
Deane, Adam M
Du, Bin
Einav, Sharon
Esteban, Andrés
Gajic, Ognjen
Galvagno, Samuel M
Guérin, Claude
Jaber, Samir
Khilnani, Gopi C
Koh, Younsuck
Lascarrou, Jean-Baptiste
Machado, Flavia R
Malbrain, Manu L N G
Mancebo, Jordi
McCurdy, Michael T
McGrath, Brendan A
Mehta, Sangeeta
Mekontso-Dessap, Armand
Mer, Mervyn
Nurok, Michael
Park, Pauline K
Pelosi, Paolo
Peter, John V
Phua, Jason
Pilcher, David V
Piquilloud, Lise
Schellongowski, Peter
Schultz, Marcus J
Shankar-Hari, Manu
Singh, Suveer
Sorbello, Massimiliano
Tiruvoipati, Ravindranath
Udy, Andrew A
Welte, Tobias
Myatra, Sheila N
Date
2021-03-16Journal
Critical care (London, England)Publisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
Using a Delphi process, an international panel of 39 experts developed clinical practice statements on the respiratory management of C-ARF in areas where evidence is absent or limited. Agreement was defined as achieved when > 70% experts voted for a given option on the Likert scale statement or > 80% voted for a particular option in multiple-choice questions. Stability was assessed between the two concluding rounds for each statement, using the non-parametric Chi-square (χ2) test (p < 0·05 was considered as unstable).Keyword
COVID 19 invasive mechanical ventilationCOVID-19 acute respiratory distress syndrome
COVID-19 high flow nasal oxygen
COVID-19 respiratory management
COVID-19 ventilatory management
Respiratory distress syndrome adult
Identifier to cite or link to this item
http://hdl.handle.net/10713/15104ae974a485f413a2113503eed53cd6c53
10.1186/s13054-021-03491-y
Scopus Count
Related articles
- [Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].
- Authors: Pfeifer M, Ewig S, Voshaar T, Randerath W, Bauer T, Geiseler J, Dellweg D, Westhoff M, Windisch W, Schönhofer B, Kluge S, Lepper PM
- Issue date: 2020 Jun
- Emergency Department Management of Severe Hypoxemic Respiratory Failure in Adults With COVID-19.
- Authors: Wilcox SR, Condella A
- Issue date: 2021 Jun
- Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.
- Authors: Pfeifer M, Ewig S, Voshaar T, Randerath WJ, Bauer T, Geiseler J, Dellweg D, Westhoff M, Windisch W, Schönhofer B, Kluge S, Lepper PM
- Issue date: 2020
- Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS.
- Authors: Lentz S, Roginski MA, Montrief T, Ramzy M, Gottlieb M, Long B
- Issue date: 2020 Oct
- Optimising Ventilator Use during the COVID-19 Pandemic.
- Authors: Sheikh S, Baig MA
- Issue date: 2020 Jun
Related items
Showing items related by title, author, creator and subject.
-
Immune Correlates of COVID-19 ControlPoonia, Bhawna; Kottilil, Shyam (Frontiers Media S.A., 2020-09-29)COVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effective immunity in most individuals along with high infectiousness of the virus has resulted in massive global public health emergency. Intense efforts are on to study viral pathogenesis and immune response to help guide prophylactic and therapeutic interventions as well as epidemiological assessments like transmission modeling. To develop an effective vaccine or biologic therapeutic, it is critical to understand the immune correlates of COVID-19 control. At the same time, whether immunity in recovered individuals is effective for preventing re-infection will be important for informing interventions like social distancing. Key questions that are being investigated regarding immune response in COVID-19 which will help these efforts include, investigations of immune response that distinguishes patients with severe versus mild infection or those that recover relative to those that succumb, durability of immunity in recovered patients and relevance of developed immunity in a cured patient for protection against re-infection as well as value of convalescent plasma from recovered patients as a potential therapeutic modality. This is a broad and rapidly evolving area and multiple reports on status of innate and adaptive immunity against SARS-CoV2 are emerging on a daily basis. While many questions remain unanswered for now, the purpose of this focused review is to summarize the current understanding regarding immune correlates of COVID-19 severity and resolution in order to assist researchers in the field to pursue new directions in prevention and control. © Copyright © 2020 Poonia and Kottilil.
-
Review of COVID-19 Myocarditis in Competitive Athletes: Legitimate Concern or Fake News?Khan, Zulqarnain; Na, Jonathan S; Jerome, Scott (Frontiers Media S.A., 2021-07-14)
-
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.Fraiman, Joseph; Erviti, Juan; Jones, Mark; Greenland, Sander; Whelan, Patrick; Kaplan, Robert M; Doshi, Peter (Elsevier, 2022-08-30)Introduction: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials. Methods: Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728 and NCT04470427), focusing analysis on Brighton Collaboration adverse events of special interest. Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI -23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI -3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39). Discussion: The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.